Linked Life Data

15142653

Source:http://linkedlifedata.com/resource/pubmed/id/15142653

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2004-5-14
pubmed:abstractText
Bisphosphonates, effectively used for metastatic bone disease and hypercalcemia, may evidentially have antiangiogenic properties. However, mechanism(s) of antiangiogenic effects of bisphosphonates are not fully understood. Their most pronounced effect is on metabolism of calcium, which is a main point of intersection for many distinct molecular signaling pathways that promote and modulate angiogenesis. An elevation of Ca(2+) plays a role in the mitogenic and secretory effects of growth factors. Some preclinical clues imply that antiangiogenic effects of bisphosphonates are related to its well-known hypocalcemic activity. Consequently, it may not be right to routinely recommend vitamin D and calcium supplementation to correct hypocalcemia unless it is symptomatic.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0306-9877
pubmed:author
pubmed:issnType
Print
pubmed:volume
62
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
942-4
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Hypocalcemic effect of zoledronic acid or other bisphosphonates may contribute to their antiangiogenic properties.
pubmed:affiliation
Hacettepe University Institute of Oncology, Medical Oncology, 06100 Sihhiye, Ankara, Turkey. saksoy07@yahoo.com
pubmed:publicationType
Journal Article